Last reviewed · How we verify
GSK208141
GSK208141 is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) that reduces blood glucose by increasing urinary glucose excretion.
GSK208141 is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) that reduces blood glucose by increasing urinary glucose excretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | GSK208141 |
|---|---|
| Also known as | Herpes simplex vaccine, gD2-AS04 vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in the urine. This mechanism lowers blood glucose levels independently of insulin secretion and has been shown to provide cardiovascular and renal protective benefits beyond glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
Key clinical trials
- Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old (PHASE3)
- Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults (PHASE1)
- Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine (PHASE3)
- Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease (PHASE3)
- Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects (PHASE3)
- Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines (PHASE1, PHASE2)
- Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK208141 CI brief — competitive landscape report
- GSK208141 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI